Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Strontium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources
PubMed1964

STUDIES ON THE INHIBITION OF INTESTINAL ABSORPTION OF RADIOACTIVE STRONTIUM. 3. THE EFFECT OF ADMINISTRATION OF SODIUM ALGINATE IN FOOD AND IN DRINKING WATER.

A method is reported which permits selective suppression of absorption of radioactive strontium from ingested food material, permitting calcium to be available to the body. Studies were carried out by measuring bone uptake of Sr(89) and Ca(45) when various amounts of sodium alginate were fed with the diet. Long-term studies were made in which two different levels of radioactivity were used, to determine the pattern of Sr(89) deposition with continuous intake of binding agent. It was found that administration of sodium alginate as a jelly overcomes the problem of constipation and effectively reduces Sr(89) uptake, up to 83%. This fact represents a significant finding with respect to the use of the compound in human subjects. Addition of sodium alginate to drinking water is effective with low levels of Sr(89) intake.This naturally occurring water-soluble macromolecular substance possesses several advantages in use for the suppression of absorption of radioactive strontium when compared with synthetic ion exchange resins: there is no disturbance of electrolyte balance; efficiency is not reduced by treatment over a prolonged period of time; and finally, the product is palatable.

Alginates↗
PubMed1993

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

Trabecular bone loss in estrogen deficiency is associated with enhanced bone resorption with a smaller increase in bone formation. We previously reported that low doses of strontium can increase trabecular bone volume in rodents by affecting bone resorption and formation. In this study we determined the effect of a new divalent strontium salt (S12911) on bone loss induced by E2 deficiency. Sprague-Dawley female rats (230 g, n = 15-25 per group) were sham operated or ovariectomized (OVX) and treated with 17 beta-estradiol (E2, 10 micrograms/kg/day, sc) or S12911 by gavage at the dose of 77, 154, or 308 mg/kg/day or the vehicle. Treatment for 60 days with S12911 resulted in a dose-dependent increase in plasma, urine, and bone strontium concentrations without any deleterious effect on total or skeletal growth. OVX rats were osteopenic compared to sham rats as shown by decreased femoral dry bone weight and mineral content measured on bone ash and by DXA. Treatment of OVX rats with S12911 prevented bone loss as bone ash and bone mineral content were restored to the values in sham rats. Trabecular bone volume measured by histomorphometry on the tibial metaphysis was decreased by 46% in OVX rats and was corrected by E2. Treatment of OVX rats with S12911 increased the trabecular bone volume by 30-36%. Histomorphometric indices of bone resorption (osteoclast surface and number) were increased in OVX rats and were reduced by S12911 to the levels in sham rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorptiometry, Photon↗
PubMed1997

Preparation and Characterization of Barium-Strontium Hydroxyapatites

Barium-strontium hydroxyapatite solid solutions with different molar ratio Ba/(Ba + Sr) were synthesized by a wet method and characterized by various means. The solid solution particles could be prepared at molar ratios ranging from 0 to 1; however, Ba2+ ions were more difficult to be incorporated into hydroxyapatite crystals compared to Sr2+ ions. With increasing Ba2+ content, the particles grew and finally turned into pure rod-shaped barium hydroxyapatite particles with a size of ca. 0.2 x 2 &mgr;m. The resulting particles were agglomerates consisted of primary fine particles except for strontium hydroxyapatite. The molar ratios (Ba + Sr)/P of all the particles were larger than the stoichiometric ratio of 1.67, suggesting that CO32- ions, OH- ions, and/or H2O molecules substitute for PO43- ions in the crystal lattices. The amount of CO2 adsorbed irreversibly on the particles increased with increasing (Ba + Sr)/P except for strontium hydroxyapatite and fitted a curve with a minimum at a cation/P ratio of ca. 1.56 as well as other HAPs.

Journal Article↗
PubMed1999

A Comparison of Strontium Sorption to Hydrous Aluminum, Iron, and Manganese Oxides.

Strontium sorption to hydrous aluminum (HAO) and manganese (HMO) oxides was studied using macroscopic studies on short- and long-term bases. These studies were compared with previous results for strontium sorption to hydrous ferric oxide (HFO). Sorption to these microporous oxides can be described as a two-step process: a rapid and reversible adsorption reaction to the external surface including the macropores is followed by a slow surface diffusion along the micropore walls of the oxides. Strontium adsorption is a physical type of reaction, where the sorbate retains its hydration sheath. Because the relationship between the amount sorbed and the bulk aqueous concentration was linear (over six orders of magnitude), the range of surface sites can be described with one average type of site. Thermodynamically, this adsorption is an entropy-driven endothermic reaction. Transient studies revealed surface diffusion coefficients ranged from 10(-12) to 10(-11) cm(2)/s; these diffusivities were compared to theoretical diffusivities using site activation theory. Results observed in these studies are consistent with those of HFO where for all the oxides, the energy barrier between sites is approximately equivalent. The long-term studies revealed as much as 90% of the total sites were located on the internal surfaces of the hydrous oxides. Therefore, current transport models must include the contribution from intraparticle diffusion to accurately describe the migration of Sr in the aquatic environments. Copyright 1999 Academic Press.

Journal Article↗
PubMed2003

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.

The aim of the PREVOS study (PREVention Of early postmenopausal bone loss by Strontium ranelate) and the STRATOS study (STRontium Administration for Treatment of OSteoporosis) was to determine the minimum dose at which strontium ranelate (SR) is effective in, respectively, the prevention of bone loss in early postmenopausal nonosteoporotic women and the treatment of postmenopausal vertebral osteoporosis. Both studies were randomized, double-blind, placebo-controlled, dose-finding studies in parallel groups and lasted 2 years. In the PREVOS study, 160 early postmenopausal women were randomized to receive placebo, SR 125 mg/day, 500 mg/day or 1 g/day. In the STRATOS study, 353 osteoporotic postmenopausal women with at least one previous vertebral fracture and a lumbar T-score <-2.4 were randomized to receive placebo, SR 500 mg/day, 1 g/day or 2 g/day. In both studies, the primary efficacy parameter was lumbar bone mineral density (BMD) measured by dual-energy X-ray absorptiometry. Secondary efficacy criteria included incidence of new vertebral deformities (in the STRATOS study only) and biochemical markers of bone metabolism. In the PREVOS study, the increase in lumbar BMD from baseline in the 1 g/day group (+5.53%) was significantly different from the decrease in the placebo group ( p<0.001). In the STRATOS study, the annual increase in lumbar BMD in the 2 g/day group (+7.3% per year) was significantly higher than in the placebo group ( p<0.001). There was a significant reduction in the number of patients experiencing new vertebral deformities in the second year of treatment in the 2 g/day group (relative risk: 0.56; 95% confidence interval: 0.35, 0.89). In both studies, there was a significant increase in the bone formation marker (bone alkaline phosphatase) in the higher-dose group. Urinary excretion of the marker of bone resorption (cross-linked N-telopeptide) was lower with SR than with placebo in the STRATOS study. SR was very well tolerated in both studies. The minimum dose at which SR is effective in preventing bone loss in early postmenopausal nonosteoporotic women and in the treatment of postmenopausal osteoporosis is 1 g/day and 2 g/day, respectively.

Aged↗
PubMed2005

Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis.

The antifracture efficacy of strontium ranelate, a compound with a novel mechanism of action on bone, has been assessed in two large, randomized, controlled trials conducted in postmenopausal women. Strontium ranelate was given at a daily dose of 2 g, and all women received calcium and vitamin D supplements. In women with established osteoporosis there was a 41% reduction in vertebral fractures over 3 years' treatment [relative risk (RR) 0.59; 95% confidence interval (CI) 0.48-0.73; P<0.001]; significant reductions were also seen after only 1 year of treatment. The beneficial effect was also seen for clinical vertebral fractures: over 3 years there was a significant reduction in new clinical vertebral fractures (RR 0.62; 95% CI 0.47-0.83; P<0.001); this reduction was also observed during the first year of treatment (RR 0.48; 95% CI 0.29-0.80; P=0.003). Over the 3-year treatment period significantly fewer patients had height loss and fewer patients reported new or worsening back pain in the treated group than in the control group. These results demonstrate that strontium ranelate is a new therapeutic option in the prevention of osteoporotic vertebral fractures in postmenopausal women.

Aged↗
PubMed2003

[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].

The therapy of osteoporosis is mostly based upon the use of drugs which inhibit bone resorption. Among these, the bisphosphonate family is the best known and mostly used by clinicians. Both second and third generation bisphosphonates, like alendronate and risedronate, are now available as weekly tablets which have facilitated the patient compliance to treatment together with a decreased occurrence of gastrointestinal side effects. These compounds are used efficiently to treat postmenopausal osteoporosis and osteoporosis of men as well. Their use did provide good evidence of increased bone mineral density (BMD) and a reduction in fracture rates. The use of intravenous bisphosphonates such as Zoledronate, Ibandronate and Pamidronate remains in most of the cases limited to special indications such as intolerance to the oral formulations and treatment of patients with bone metastases. The selective estrogen modulators (SERM's) family is limited to a single product on the market as of now, Raloxifene, which does inhibit bone resorption and is well documented by postmenopausal women to increase BMD and reduce vertebral fractures. In addition, a large range of positive nonosseous effects have been documented such as the reduction of the incidence of breast cancer. Other substances do have a strong anabolic effect such as Teriparatide, a recombinant human formulation of PTH 1-34. This compound has demonstrated good efficacy in postmenopausal women, increasing vertebral and hip BMD and reducing the incidence of fractures at both sites. The exact role of Teriparatide in the clinical setting is still open but its overall impact in the therapy of osteoporosis could be major due to its major efficiency over shorter periods of time. Strontium ranelate, a new divalent Strontium salt taken orally, acts both as an anti-catabolic and anabolic agent. The first results provided with strontium ranelate are very promising due to its major effect on the increase in BMD both at the vertebral and hip sites and its ability to reduce the incidence of fractures at both locations. Additional data are awaited to confirm these initial positive results.

Aged↗
PubMed2004

In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor.

The extracellular calcium-sensing receptor (CaSR) is activated by divalent cations and might mediate some of the effects of strontium ranelate, a new drug for the prevention and treatment of post-menopausal osteoporosis. Here, we showed that the maximal effect of Sr(2+) was comparable to that observed for Ca(2+) for both the cloned rat CaSR expressed in Chinese hamster ovary [CHO(CaSR)] cells and the mouse CaSR constitutively expressed in AtT-20 cells as measured by the accumulation of [(3)H]inositol phosphates (IP) resulting from CaSR activation. Strontium ranelate also displayed comparable agonist activity for the CaSR in both cell lines. Sodium ranelate did not stimulate the IP response in CHO(CaSR) cells. The IP response resulting from activation of other G-protein-coupled receptors was potentiated by Sr(2+), suggesting that entry of Sr(2+) into the cells might influence phospholipase C activity. Modulation of the CaSR activity in bone cells by strontium ranelate may contribute to its reported antiosteoporotic effects.

Animals↗
PubMed2002

Salen-type compounds of calcium and strontium.

Salen complexes of the heavy alkaline-earth metals, calcium and strontium, were prepared by the reaction of various salen(t-Bu)H(2) ligands with the metals in ethanol. Six new calcium and strontium compounds, [Ca(salen(t-Bu))(HOEt)(2)(thf)] (1), [Ca(salen(t-Bu))(HOEt)(2)] (2), [Ca(salpen(t-Bu))(HOEt)(3)] (3), [Ca(salophen(t-Bu))(HOEt)(thf)] (4), [Sr(salen(t-Bu))(HOEt)(3)] (5), and [Sr(salophen(t-Bu))(HOEt)(thf)(2)] (6), were formed in this way with the quatridentate Schiff-base ligands N,N'-bis(3,5-di-tert-butylsalicylidene)ethylenediamine (salen(t-Bu)H(2)), N,N'-bis(3,5-di-tert-butylsalicylidene)-1,3-propanediamine (salpen(t-Bu)H(2)), and N,N'-o-phenylenebis(3,5-di-tert-butylsalicylideneimine (salophen(t-Bu)H(2)). Initially, ammonia solutions of the metals were combined with the salen(t-Bu)H(2) ligands, and in the reaction of strontium with salen(t-Bu)H(2), the unusual tetrametallic cluster [(OC(6)H(2)(t-Bu)(2)CHN(CH(2))(2)NH(2))Sr(mu(3)-salean(t-Bu)H(2))Sr(mu(3)-OH)](2) (7) was produced (salean(t-Bu)H(4) = N,N'-bis(3,5-di-tert-butyl-2-hydroxybenzyl)ethylenediamine). In this compound, the imine bonds of the salen(t-Bu)H(2) ligand were reduced to form the known ligands salean(t-Bu)H(4) and (HO)C(6)H(2)(t-Bu)(2)CHN(CH(2))(2)NH(2). Compounds 1, 5, 6, and 7 were structurally characterized by single-crystal X-ray diffraction. Crystal data for 1 (C(44)H(74)CaN(2)O(6)): triclinic space group P(-)1, a = 8.3730(10) A, b = 14.8010(10) A, c = 18.756(2) A, alpha = 72.551(10) degrees, beta = 81.795(10) degrees, gamma = 78.031(10) degrees, Z = 2. Crystal data for 5 (C(38)H(64)SrN(2)O(5)): monoclinic space group P2(1)/c, a = 23.634(3) A, b = 8.4660(10) A, c = 24.451(3) A, beta = 101.138(10) degrees, Z = 4. Crystal data for 6 (C(46)H(67)N(2)O(5)Sr): orthorhombic space group P2(1)2(1)2(1), a = 10.5590(2) A, b = 16.2070(3) A, c = 26.7620(6) A, Z = 4. Crystal data for 7 (C(98)H(156)N(8)O(8)Sr(4)): triclinic space group P(-)1, a = 14.667(1) A, b = 15.670(1) A, c = 18.594(2) A, alpha = 92.26(1) degrees, beta = 111.84(1) degrees, gamma = 117.12(1) degrees, Z = 4.

Journal Article↗
PubMed2001

New efficient calixarene amide ionophores for the selective removal of strontium ion from nuclear waste: synthesis, complexation, and extraction properties.

Three novel lower rim hexamide derivatives 5(6), 7(6), and 9(6) of p-hydroxycalix[6]arene and four octamides 5(8), 7(8)-9(8) derived from the corresponding p-hydroxycalix[8]arene were synthesized, and their potential as extractants in radioactive waste treatment was evaluated, in comparison with upper rim analogues 12(6) and 12(8) and other existing selective neutral ionophores currently used in radioactive waste treatment. Extraction of alkali and alkaline earth metal picrates from water to dichloromethane, and of the corresponding nitrates from acidic water solution simulating radioactive waste, to 2-nitrophenyl hexyl ether (NPHE), showed that the lower rim amides extract divalent cations much better than monovalent ones. The upper rim hexa-12(6) and octamide 12(8) are very inefficient ligands, hardly extracting any cation. In all cases, p-alkoxy octamides are more efficient and selective extractants than the corresponding hexamides. In the case of simulated waste solutions, the distribution coefficients for strontium removal by octamides (6.5 < D(Sr) < 30) are much higher than the corresponding value (D(Sr)) found for dicyclohexyl-18-crown-6 (DC18C6), and the same applies for the strontium/sodium selectivity, which is 6500 < D(Sr)/D(Na) < 30 000 for octamides and 47 for DC18C6. ESI-MS, UV-vis, and X-ray crystal structure studies give consistent results and indicate the formation of 2:1 (cation/ligand) strontium complexes for all octamides tested. Stability constants were determined in homogeneous methanol solution for alkali metal (log beta(11) < or = 2), calcium (4.3 < or = log beta(11) < or = 6.0; 9.4 < or = log beta(21) < or = 12.0), and strontium (5.6 < or = log beta(11) < or = 12.3) ions using a UV-vis competition method with 1-(2-pyridylazo)-2-naphthol (PAN). They confirm the high efficiency and high divalent/monovalent selectivity found in metal ion extraction experiments for the new octamide ligands. Evidence for a positive cooperative effect between the two metal ion binding sites was obtained in the case of the Ca(2+) complex of octamide 1(8).

Journal Article↗
PubMed1999

Parthenogenetic activation of mouse oocytes by exposure to strontium as a source of cytoplasts for nuclear transfer.

Cell-cycle phase of the donor and recipient cells at the moment of nuclear transfer influences subsequent development of the reconstituted embryo. In order to study this effect, the precise cell-cycle phase of the recipient oocyte at the time of fusion must be known and this depends on reliable activation of oocytes in a protocol that has a low incidence of spontaneous activation. Mouse oocytes recovered before (8-10 hours post-human chorionic gonadotropin [hCG]) and after ovulation (14 and 18 hours post-hCG) were exposed to strontium ions in calcium magnesium-free M16 culture medium. The effect on development of haploid parthenotes of post-hCG age of the oocyte, the duration of exposure, and strontium concentration in the medium was determined. These experiments established a reliable method of parthogenetic activation of recently ovulated mouse oocytes, involving the culture of oocytes for 60 minutes in 25 mM strontium in a calcium magnesium-free M16 medium. This method of activation was also able to induce activation of preovulatory oocytes after a preincubation period in vitro. Only a low incidence of spontaneous activation was observed if oocytes were recovered before or immediately after ovulation (14 hours after hCG).

Journal Article↗
PubMed2006

Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis.

UNLABELLED: Currently available medications, such as bisphosphonates, selective estrogen receptor modulators, and teriparatides, have shown their ability to reduce vertebral and/or nonvertebral fractures. Questions remain regarding their long-term innocuousness and several studies showed that adhering to currently marketed anti-osteoporotic medications remain sub-optimal. There is, therefore, an urgent need for the development of new effective, safe, and user-friendly medications to optimize the treatment of postmenopausal osteoporosis. The current review was designed to assess, through an extensive literature search, the antifracture efficacy of strontium ranelate on the axial and appendicular skeleton. Two multinational Phase 3 clinical trials have shown its efficacy and safety in the treatment of postmenopausal osteoporosis. In the Spinal Osteoporosis Therapeutic Intervention trial, strontium ranelate (2 g/day) treatment reduced the relative risk of a new vertebral fracture by 41% after 3 years compared with placebo. Data from the Treatment of Peripheral Osteoporosis study showed a 16% reduction in the relative risk of nonvertebral fracture in all patients and a 36% reduction in hip fracture in high-risk patients. Strontium rane-late reduces the risk of all fragility fractures and is well tolerated, which makes it a new first-line alternative in the treatment of postmenopausal osteoporosis. LEVEL OF EVIDENCE: Therapeutic study, Level II (lesser quality randomized controlled trial [eg, < 80% followup, no blinding, or improper randomization]). See the Guidelines for Authors for a complete description of the levels of evidence.

Animals↗
PubMed1967

Relation Between Calcium and Strontium Transport Rates as Determined Simultaneously in the Primary Root of Zea mays.

Root segments of Zea mays 55 mm long, were exposed to nutrient containing (85)Sr and (45)Ca tracers. Translocation rather than uptake was measured, using a newly-designed glass compartmentation system and validated tracer analytic model. Ca transport from solutions containing between 0.25 and 5.0 mm Ca was only slightly affected by concentration, but translocation from 0.25 to 0.05 mm solutions was markedly reduced. Maximum transport of strontium from nutrient containing 0.05 mm Ca was twice that from 2.5 mm Ca, and also twice the maximum calcium transported. Thus, under the condition simulating calcium depletion, i.e., 0.05 mm Ca, greater amounts of strontium were transported. In these cases the solutions also contained stable strontium at concentrations between 0.25 and 5.0 mm. In simultaneous determinations, the ratio of Sr to Ca moved was exactly equal to the ratio of their concentrations in nutrient solution, and there was no evidence of discrimination. Dinitrophenol reduced transport of Sr and Ca to an equivalent extent, amounting to between 2 and 9% of non-treated control levels.

Journal Article↗
PubMed2006

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.

UNLABELLED: Strontium ranelate produces an early and sustained reduction of both vertebral and nonvertebral fractures in patients > or = 80 years of age. INTRODUCTION: About 25-30% of the population burden of all fragility fractures in the community arise from women > or = 80 years of age, because this population is at high risk for all types of fracture, particularly nonvertebral fractures. Despite this, evidence that therapies reduce the risk of both vertebral and nonvertebral fractures in this group is lacking. The aim of this study was to determine whether strontium ranelate, an agent that reduces the risk of vertebral and nonvertebral fractures in postmenopausal women >50 years of age, also reduces fractures in the elderly. MATERIALS AND METHODS: An analysis based on preplanned pooling of data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]) included 1488 women between 80 and 100 years of age followed for 3 years. Yearly spinal X-rays were performed in 895 patients. Only radiographically confirmed nonvertebral fractures were included. RESULTS: Baseline characteristics did not differ in placebo and treatment arms. In the intent-to-treat analysis, the risk of vertebral, nonvertebral, and clinical (symptomatic vertebral and nonvertebral) fractures was reduced within 1 year by 59% (p = 0.002), 41% (p = 0.027), and 37% (p = 0.012), respectively. At the end of 3 years, vertebral, nonvertebral, and clinical fracture risks were reduced by 32% (p = 0.013), 31% (p = 0.011), and 22% (p = 0.040), respectively. The medication was well tolerated, and the safety profile was similar to that in younger patients. CONCLUSIONS: Treatment with strontium ranelate safely reduces the risk of vertebral and nonvertebral fractures in women with osteoporosis > or = 80 years of age. Even in the oldest old, it is not too late to reduce fracture risk.

Age Factors↗
PubMed2004

[Preclinical evaluation of strontium ranelate in bone quality].

Strontium ranelate is the first treatment able to stimulate bone formation and to inhibit bone resorption inducing a positive bone balance. In intact female rats, strontium ranelate increased bone mass and strength dose-dependently at the level of the vertebral body and midshaft femur. An increment of plastic energy was also observed and suggests that bone treated by strontium ranelate is able to cumulate more damages before fracture than normal bone.

Animals↗
PubMedDate not supplied

[Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].

Osteoporosis has become a global public health issue due to the fact that the world population has gotten older. In the past ten years we have witnessed a great improvement in the treatment of postmenopausal osteoporosis. The anti-resorptive drugs are the most presribed ones. In the last couple of years osteoanabolic drug, a teriparatid, was introduced into the clinical use, and recently a strontium ranelate has occured as a drug with osteoanabolic and antiresorptive effect in bone formation. Clinical trials (phase III) have proved the efficiency of strontium ranelate in postmenopausal osteoporosis treatment. Strontium ranelate is a drug characterized by the new paradigm of action mechanism on bone, which has its place among the already well-proven drugs in postmenopausal osteoporosis treatment.

Bone Density Conservation Agents↗
PubMed2003

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.

BACKGROUND: The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. METHODS: Patients with androgen-independent prostate carcinoma and painful osteoblastic bone metastases were eligible. On a 12-week course, patients received gemcitabine (600 mg/m(2) or 800 mg/m(2)) on Days 1, 8, 15, 43, 50, and 57. A single dose of strontium-89 (55 microCi/kg) was administered on Day 8. RESULTS: Fifteen patients were registered, and all were assessable for response and toxicity. Four patients were treated at Dose Level 1 (gemcitabine 600 mg/m(2)) without dose-limiting toxicity. Eleven patients received a total of 13 courses at Dose Level 2 (gemcitabine 800 mg/m(2)). Platelet nadirs of 25000-50000 platelets per microL were common at Dose Level 2, and 1 patient had Grade 4 thrombocytopenia that was dose-limiting. Granulocyte nadirs up to < 500 granulocytes per microL occurred in 4 patients at Dose Level 2 and were reversible. There were no responses, as measured by prostate specific antigen concentration, although 6 patients (40%) had stable disease. CONCLUSIONS: The authors concluded that 800 mg/m(2) gemcitabine was the maximum tolerated dose for the combination. The study was terminated on the basis that an overall response rate > than 10% was unlikely. Further study at this dose level and schedule is not warranted. .

Aged↗
PubMed1966

Bile and the absorption of strontium and iron.

1. Strontium absorption was studied in vivo with loops of ileum in rachitic chicks and found to be increased by vitamin D(3), bile salts and sodium lauryl sulphate. 2. Bile salts and sodium lauryl sulphate rendered strontium soluble in butanol-benzene (1:1, v/v). 3. Bile was not concerned in the absorption of iron in rats from its water-soluble form, ferrous sulphate. 4. Ligation of the bile ducts in rats caused a decrease in the absorption of iron presented as its sparingly soluble phosphate. 5. The effect of bile on cation absorption is discussed.

Animals↗